AI-Designed Drug Makes Patients' Blood Look Biologically Younger, Study Shows

Key Points:

• A drug called rentosertib, designed with AI to treat idiopathic pulmonary fibrosis (IPF), was found to make blood protein profiles of patients appear biologically younger according to six different biological aging clocks.
• The study analyzed blood samples from 42 IPF patients in a 12-week trial, revealing that all six aging clocks detected a shift toward a lower predicted biological age in those treated with rentosertib, especially after four weeks.
• Rentosertib altered levels of 326 proteins related to lung scarring, inflammation, energy use, and cellular stress, suggesting effects beyond lung disease treatment, though the biological age reduction plateaued after four weeks.
• Limitations include the small sample size, short duration, and inability to distinguish whether the drug improved aging processes or simply reduced disease effects; further studies in larger, healthier populations are needed.
• While promising, rentosertib is not yet confirmed as an anti-aging drug, but the findings highlight potential for therapies targeting aging-related biological processes alongside specific diseases.